FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Assembly Biosciences, Inc. Stock AnalysisComprehensive stock analysis for Assembly Biosciences, Inc. (ASMB) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisASMB
ASMB
Assembly Biosciences, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ASMB
Home🔹Stocks🔹Assembly Biosciences, Inc.

Assembly Biosciences, Inc.

ASMB•NASDAQ

Assembly Biosciences, Inc.

ASMB•NASDAQ
Market cap
$406.38M
Sentiment

Your view on ASMB

Mkt Cap
$406.38M
Sentiment
Your view
ASMB
Assembly Biosciences, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ASMB
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Assembly Biosciences, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Jason A. Okazaki
Headquarters
331 Oyster Point Boulevard, South San Francisco, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Jason A. Okazaki
Headquarters
331 Oyster Point Boulevard, South San Francisco, CA, US
Description

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News